{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T18:37:18Z","timestamp":1769279838132,"version":"3.49.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100002701","name":"Ministry of Education","doi-asserted-by":"publisher","award":["2012R1A1A2041534"],"award-info":[{"award-number":["2012R1A1A2041534"]}],"id":[{"id":"10.13039\/501100002701","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002701","name":"Ministry of Education","doi-asserted-by":"publisher","award":["2013R1A1A2066108"],"award-info":[{"award-number":["2013R1A1A2066108"]}],"id":[{"id":"10.13039\/501100002701","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.bbrc.2016.11.122","type":"journal-article","created":{"date-parts":[[2016,11,23]],"date-time":"2016-11-23T07:46:36Z","timestamp":1479887196000},"page":"843-848","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Inhibition of ERK activity enhances the cytotoxic effect of peroxisome proliferator-activated receptor \u03b3 (PPAR\u03b3) agonists in HeLa cells"],"prefix":"10.1016","volume":"482","author":[{"given":"Ha Kyun","family":"Chang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dae Seong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung Jun","family":"Chae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minsun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun-Pyo","family":"Myong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keun Ho","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myoung Woo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tae Chul","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2016.11.122_bib1","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1007\/s10552-009-9317-z","article-title":"Incidence trends of invasive cervical cancer in the United States by combined race and ethnicity","volume":"20","author":"Barnholtz-Sloan","year":"2009","journal-title":"Cancer Causes Control CCC"},{"key":"10.1016\/j.bbrc.2016.11.122_bib2","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1002\/cncr.24843","article-title":"Cervical cancer incidence among 6 asian ethnic groups in the United States, 1996 through 2004","volume":"116","author":"Wang","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.bbrc.2016.11.122_bib3","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1002\/cncr.20877","article-title":"Mortality trends for cervical squamous and adenocarcinoma in the United States. Relation to incidence and survival","volume":"103","author":"Sherman","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.bbrc.2016.11.122_bib4","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bbrc.2016.11.122_bib5","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.1749-6632.2002.tb04260.x","article-title":"PPARgamma, an X-ceptor for Xs","volume":"967","author":"Koutnikova","year":"2002","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.bbrc.2016.11.122_bib6","doi-asserted-by":"crossref","first-page":"342","DOI":"10.3109\/07853899908995901","article-title":"Peroxisome proliferator-activated receptor-gamma: a versatile metabolic regulator","volume":"31","author":"Rocchi","year":"1999","journal-title":"Ann. Med."},{"key":"10.1016\/j.bbrc.2016.11.122_bib7","first-page":"1","article-title":"Peroxisome proliferator-activated receptor gamma and cancers","volume":"9","author":"Koeffler","year":"2003","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.bbrc.2016.11.122_bib8","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1097\/00001622-200101000-00015","article-title":"Peroxisome proliferator-activated receptors: roles in tumorigenesis and chemoprevention in human cancer","volume":"13","author":"Park","year":"2001","journal-title":"Curr. Opin. Oncol."},{"key":"10.1016\/j.bbrc.2016.11.122_bib9","doi-asserted-by":"crossref","first-page":"465","DOI":"10.2174\/1568011043352678","article-title":"Can PPAR gamma ligands be used in cancer therapy?","volume":"4","author":"Rumi","year":"2004","journal-title":"Curr. Med. Chem. Anti Cancer Agents"},{"key":"10.1016\/j.bbrc.2016.11.122_bib10","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1038\/jid.2008.346","article-title":"In\u00a0vitro and in\u00a0vivo anti-melanoma effects of ciglitazone","volume":"129","author":"Botton","year":"2009","journal-title":"J.\u00a0Investig. Dermatol."},{"key":"10.1016\/j.bbrc.2016.11.122_bib11","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0092-8674(00)81575-5","article-title":"PPARgamma promotes monocyte\/macrophage differentiation and uptake of oxidized LDL","volume":"93","author":"Tontonoz","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.bbrc.2016.11.122_bib12","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1006\/bbrc.1999.1071","article-title":"PPARgamma activation induces the expression of the adipocyte fatty acid binding protein gene in human monocytes","volume":"261","author":"Pelton","year":"1999","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbrc.2016.11.122_bib13","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/347645a0","article-title":"Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators","volume":"347","author":"Issemann","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2016.11.122_bib14","first-page":"649","article-title":"Peroxisome proliferator-activated receptors: nuclear control of metabolism","volume":"20","author":"Desvergne","year":"1999","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.bbrc.2016.11.122_bib15","first-page":"5068","article-title":"The peroxisome proliferator-activated receptor gamma (PPARgamma) ligands 15-deoxy-Delta12,14-prostaglandin J2 and ciglitazone induce human B lymphocyte and B cell lymphoma apoptosis by PPARgamma-independent mechanisms","volume":"177","author":"Ray","year":"2006","journal-title":"J.\u00a0Immunol. Baltim. Md. 1950"},{"key":"10.1016\/j.bbrc.2016.11.122_bib16","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1126\/science.123.3191.309","article-title":"On the origin of cancer cells","volume":"123","author":"Warburg","year":"1956","journal-title":"Sci. (New York, N.Y.)"},{"key":"10.1016\/j.bbrc.2016.11.122_bib17","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/nrc1478","article-title":"Why do cancers have high aerobic glycolysis?","volume":"4","author":"Gatenby","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbrc.2016.11.122_bib18","first-page":"5494","article-title":"Down-Regulation of prostate-specific antigen expression by ligands for peroxisome proliferator-activated receptor gamma in human prostate cancer","volume":"60","author":"Hisatake","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbrc.2016.11.122_bib19","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1124\/mol.107.035287","article-title":"Thiazolidinediones modulate the expression of beta-catenin and other cell-cycle regulatory proteins by targeting the F-box proteins of Skp1-Cul1-F-box protein E3 ubiquitin ligase independently of peroxisome proliferator-activated receptor gamma","volume":"72","author":"Wei","year":"2007","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bbrc.2016.11.122_bib20","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.etp.2008.05.006","article-title":"Modulation of cell growth and PPARgamma expression in human colorectal cancer cell lines by ciglitazone","volume":"60","author":"Yaacob","year":"2008","journal-title":"Exp. Toxicol. Pathol. Off. J. Ges. Toxikol. Pathol."},{"key":"10.1016\/j.bbrc.2016.11.122_bib21","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.1016\/j.febslet.2007.06.012","article-title":"Pro-MMP-2 activation by the PPARgamma agonist, ciglitazone, induces cell invasion through the generation of ROS and the activation of ERK","volume":"581","author":"Kim","year":"2007","journal-title":"FEBS Lett."},{"key":"10.1016\/j.bbrc.2016.11.122_bib22","doi-asserted-by":"crossref","first-page":"3951","DOI":"10.1073\/pnas.96.7.3951","article-title":"Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma","volume":"96","author":"Demetri","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbrc.2016.11.122_bib23","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1111\/dme.12144","article-title":"Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies","volume":"30","author":"Ferwana","year":"2013","journal-title":"Diabet. Med. J. Br. Diabet. Assoc."},{"key":"10.1016\/j.bbrc.2016.11.122_bib24","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/toxsci\/kfp256","article-title":"Effects of pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, on the urine and urothelium of the rat","volume":"113","author":"Suzuki","year":"2010","journal-title":"Toxicol. Sci. Off. J. Soc. Toxicol."},{"key":"10.1016\/j.bbrc.2016.11.122_bib25","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ejphar.2007.11.004","article-title":"Effects of 15-deoxy-Delta12, 14 prostaglandin J2 and ciglitazone on human cancer cell cycle progression and death: the role of PPARgamma","volume":"580","author":"Ferreira-Silva","year":"2008","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bbrc.2016.11.122_bib26","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S0960-9822(99)80265-6","article-title":"Induction of NF-kappaB by the Akt\/PKB kinase","volume":"9","author":"Kane","year":"1999","journal-title":"Curr. Biol. CB"},{"key":"10.1016\/j.bbrc.2016.11.122_bib27","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s12031-008-9122-2","article-title":"Evidence for involvement of ERK, PI3K, and RSK in induction of Bcl-2 by valproate","volume":"37","author":"Creson","year":"2009","journal-title":"J.\u00a0Mol. Neurosci. MN"}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X16319969?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X16319969?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T11:10:22Z","timestamp":1655464222000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X16319969"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S0006291X16319969"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2016.11.122","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibition of ERK activity enhances the cytotoxic effect of peroxisome proliferator-activated receptor \u03b3 (PPAR\u03b3) agonists in HeLa cells","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2016.11.122","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}